Important: New Login Process

We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.

  • If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
  • If you log in with a username and password, you will be prompted to set a new password before accessing your account.

Go to the Login Page to get started.

We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.

BioCentury
ARTICLE | Finance

Direct from UCB Ventures

Why UCB Ventures has pivoted from backing VC funds to making direct investments

Chris Lieu, Staff Writer
June 22, 2018 8:58 PM UTC

UCB Ventures’ recent investment in Durham, N.C.-based gene therapy play StrideBio Inc. marks the next phase in how the strategic investor plans to deploy its €150 million ($174 million) fund. After backing multiple healthcare VC funds, the venture arm of UCB S.A. (Euronext:UCB) now plans to invest directly in companies that are “higher risk” but still loosely align with UCB’s therapeutic focus.

VP and Head of UCB Ventures Erica Whittaker told BioCentury that the fund, which launched last year, initially invested an undisclosed proportion of its fund in funds run by Arix Bioscience plc, Pappas Ventures and Qiming. ...

Get Unlimited Access
Continue reading with a free trial.
Start a Free TrialLog In
Or Purchase This Article

BCIQ Company Profiles

Ucb S.A.